Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 2/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.97 |
| ▸ | MEN1 | O00255 | 4/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.97 |
| ▸ | TP53 | P04637 | 2/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.97 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL31502661 | 0.99 | CYP1A1 (0.98) | CYP1A1CYP1B1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL158627 | 0.99 | KMT2A (1.00) | CYP1A1CYP1B1MAPTSMN1; SMN2MEN1 | |
| Bromide SCHEMBL31502664 | 0.97 | CYP1A1 (0.95) | CYP1A1CYP1B1MAPTSMN1; SMN2MEN1 | |
| Bromide SCHEMBL22749605 | 0.96 | KMT2A (0.95) | CYP1A1CYP1B1MAPTSMN1; SMN2MEN1 | |
| Bromide SCHEMBL29440240 | 0.87 | CYP1A1 (0.77) | CYP1A1CYP1B1MAPTSMN1; SMN2MEN1 | |
| Bromide SCHEMBL22749646 | 0.87 | CYP1A1 (0.77) | CYP1A1CYP1B1MAPTSMN1; SMN2MEN1 | |
| Bromide SCHEMBL22749617 | 0.87 | CYP1A1 (0.77) | CYP1A1CYP1B1MAPTSMN1; SMN2MEN1 | |
| Bromide SCHEMBL29440245 | 0.87 | CYP1A1 (0.77) | CYP1A1CYP1B1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL4942836 | 0.86 | ALDH1A1 (0.77) | CYP1A1CYP1B1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL13650924 | 0.86 | MAPT (0.77) | CYP1A1CYP1B1MAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288617-A1 | Gene Therapy | OSPEDALE SAN RAFFAELE SRL (IT) | 2025-09-18 | — | — | US | claimed |
| US-20250115871-A1 | METHODS TO IMPROVE ENDURING HEMATOPOIETIC STEM CELL TRANSPLANTATION | TRAILHEAD BIOSYSTEMS INC. | 2025-04-10 | — | — | US | claimed |
| EP-4496562-A1 | COMPOSITIONS | Amazentis SA (CH) | 2025-01-29 | — | — | EP | claimed |
| US-12058986-B2 | Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements | EGENESIS, INC. (US) | 2024-08-13 | — | — | US | claimed |
| US-20240218051-A1 | MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION | GENZYME CORPORATION | 2024-07-04 | — | — | US | claimed |
| CN-117672411-B | Hormesis effect research method of traditional Chinese medicine component and application of berberine as traditional Chinese medicine component | 首都医科大学附属北京世纪坛医院 | 2024-05-14 | — | — | CN | claimed |
| US-11879004-B2 | Modified binding polypeptides for optimized drug conjugation | GENZYME CORPORATION (US) | 2024-01-23 | — | — | US | claimed |
| US-20240000935-A1 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | GENEIUS BIOTECHNOLOGY, INC. (US) | 2024-01-04 | — | — | US | claimed |
| US-20230391849-A1 | MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION | GENZYME CORPORATION | 2023-12-07 | — | — | US | claimed |
| EP-4251177-A2 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | Geneius Biotechnology, Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| CN-115410126-A | Data unbalanced weak surveillance video anomaly detection method and system | 西安交通大学 | 2022-11-29 | — | — | CN | claimed |
| CN-115049534-A | Knowledge distillation-based real-time semantic segmentation method for fisheye image | 上海交通大学 | 2022-09-13 | — | — | CN | claimed |
| US-20220251054-A1 | Analogues and Methods of Treating Rett Syndrome | UNIV CALIFORNIA (US) | 2022-08-11 | — | — | US | claimed |
| WO-2022162353-A1 | METHOD OF REDUCING THE TUMORIGENIC POTENTIAL OF A POPULATION OF MAMMALIAN STEM CELLS AFTER GENOME EDITING | Oxford Genetics Limited (GB) | 2022-08-04 | — | — | WO | claimed |
| WO-2022115641-A2 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | GENEIUS BIOTECHNOLOGY, INC. (US) | 2022-06-02 | — | — | WO | claimed |
| EP-3976796-A1 | PIFITHRIN ANALOGUES AND METHODS OF TREATING RETT SYNDROME | The Regents of the University of California (US) | 2022-04-06 | — | — | EP | claimed |
| CN-114144437-A | Engineered pH-dependent anti-CD 3 antibodies and methods of making and using the same | 阿迪马布有限责任公司 | 2022-03-04 | — | — | CN | claimed |
| US-11110126-B2 | Method of expanding NK cell and composition for culturing | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2021-09-07 | — | — | US | claimed |
| US-20190183995-A1 | METHOD OF EXPANDING NK CELL AND COMPOSITION FOR CULTURING | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2019-06-20 | — | — | US | claimed |
| US-20170119865-A1 | METHOD OF EXPANDING NK CELL AND COMPOSITION FOR CULTURING | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2017-05-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11879004-B2 | Modified binding polypeptides for optimized drug conjugation | FCGR3B, CD2BP2, FCGR2A | CYP1A1 4062/4885CYP1B1 3416/4885MAPT 1888/4885 |
| US-20220251054-A1 | Analogues and Methods of Treating Rett Syndrome | MECP2, PAX3, PAX2 | CYP1A1 4823/4885CYP1B1 4793/4885MAPT 172/4885 |
| US-20250288617-A1 | Gene Therapy | TP53, ZC3HAV1, TP53BP1 | CYP1A1 3436/4885CYP1B1 2081/4885MAPT 3744/4885 |
| US-20240218051-A1 | MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION | FCGR3B, CD2BP2, FCGR2A | CYP1A1 4062/4885CYP1B1 3416/4885MAPT 1888/4885 |
| US-20230391849-A1 | MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION | FCGR3B, CD2BP2, FCGR2A | CYP1A1 4062/4885CYP1B1 3416/4885MAPT 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.